The immuno-oncology therapy developer has amassed at least $190m of overall funding since emerging out of Stanford University.

Synthekine, a US-based immuno-oncology therapy spinout of Stanford University, has raised $108m in a series B round co-led by Deerfield Management and Janus Henderson Investors. Lilly Asia Ventures, a corporate venturing vehicle for pharmaceutical firm Eli Lilly. RA Capital Management, Rock Springs Capital, Omega Funds, Samsara BioCapital, Canaan Partners, Emerson Collective, Column Group and its…

The rest of this content is only accessible to University Venturing: News, Data, and Events - Global University Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.